Form 8-K - Current report:
SEC Accession No. 0001558370-25-004651
Filing Date
2025-04-10
Accepted
2025-04-10 08:30:59
Documents
31
Period of Report
2025-04-10
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nxtc-20250410x8k.htm   iXBRL 8-K 48181
2 EX-99.1 nxtc-20250410xex99d1.htm EX-99.1 23302
3 GRAPHIC nxtc-20250410xex99d1g001.jpg GRAPHIC 197237
4 GRAPHIC nxtc-20250410xex99d1g002.jpg GRAPHIC 271262
5 GRAPHIC nxtc-20250410xex99d1g003.jpg GRAPHIC 77138
6 GRAPHIC nxtc-20250410xex99d1g004.jpg GRAPHIC 84789
7 GRAPHIC nxtc-20250410xex99d1g005.jpg GRAPHIC 100667
8 GRAPHIC nxtc-20250410xex99d1g006.jpg GRAPHIC 77741
9 GRAPHIC nxtc-20250410xex99d1g007.jpg GRAPHIC 128444
10 GRAPHIC nxtc-20250410xex99d1g008.jpg GRAPHIC 93287
11 GRAPHIC nxtc-20250410xex99d1g009.jpg GRAPHIC 177157
12 GRAPHIC nxtc-20250410xex99d1g010.jpg GRAPHIC 141058
13 GRAPHIC nxtc-20250410xex99d1g011.jpg GRAPHIC 120147
14 GRAPHIC nxtc-20250410xex99d1g012.jpg GRAPHIC 182522
15 GRAPHIC nxtc-20250410xex99d1g013.jpg GRAPHIC 141519
16 GRAPHIC nxtc-20250410xex99d1g014.jpg GRAPHIC 145034
17 GRAPHIC nxtc-20250410xex99d1g015.jpg GRAPHIC 89470
18 GRAPHIC nxtc-20250410xex99d1g016.jpg GRAPHIC 83688
  Complete submission text file 0001558370-25-004651.txt   3079371

Data Files

Seq Description Document Type Size
19 EX-101.SCH nxtc-20250410.xsd EX-101.SCH 4099
20 EX-101.DEF nxtc-20250410_def.xml EX-101.DEF 2848
21 EX-101.LAB nxtc-20250410_lab.xml EX-101.LAB 17252
22 EX-101.PRE nxtc-20250410_pre.xml EX-101.PRE 11362
33 EXTRACTED XBRL INSTANCE DOCUMENT nxtc-20250410x8k_htm.xml XML 4849
Mailing Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705
Business Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705 240-399-4900
NextCure, Inc. (Filer) CIK: 0001661059 (see all company filings)

EIN.: 475231247 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38905 | Film No.: 25826590
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)